To facilitate the first-in-human CARAMBA trial with autologous T cells targeting the SLAMF7 antigen in refractory MM, an entirely novel manufacturing process was established, which leverages on our preclinical work [48]. The gene discussed is SLAMF7; the disease is Miyoshi myopathy.